Stocktoria

Lexeo Therapeutics, Inc. LXEO

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-11-03

Lexeo Therapeutics, Inc. statistics & valuation

Market cap$373.0M
P / B1.5×
Return on equity-40.5%
Return on capital-43.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2022202320242025
Operating margin (%)
-9252.10% 2022202320242025
Return on equity (%)
-58.50% -84.20% -40.50% 2022202320242025
Shares outstanding
1.6M 26.6M 33.1M 73.0M 2022202320242025
Net debt ($)
2022202320242025
Share buybacks ($)
2022202320242025
Return on assets (%)
-61.10% -47.50% -66.90% -37.20% 2022202320242025
Free cash flow margin (%)
-8445.30% 2022202320242025
Debt / equity (×)
2022202320242025
EPS ($)
-$36.36 -$12.40 -$3.09 -$1.86 2022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022
Operating margin———-9252.1%
Net margin———-9063.8%
FCF margin———-8445.3%
Return on assets-37.2%-66.9%-47.5%-61.1%
Return on equity-40.5%-84.2%-58.5%52.5%
Current ratio11.215.527.215.58

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.